Natural history studies have identified numerous features of disability progression in patients with multiple sclerosis (MS), and have provided valuable insight into the underlying pathology of the disease that could assist the development of new treatment strategies. A new study indicates that disability progression occurs in two stages in patients with MS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Leray, E. et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 133, 1900–1913 (2010).
Confavreux, C., Vukusic, S., Moreau, T. & Adeleine, P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343, 1430–1438 (2000).
Tremlett, H. L., Paty, D. & Devonshire, V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 66, 172–177 (2006).
Confavreux, C., Vukusic, S. & Adeleine, P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126, 770–782 (2003).
Confavreux, C. & Vukusic, S. Natural history of multiple sclerosis: a unifying concept. Brain 129, 606–616 (2006).
Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285 (1998).
Imitola, J., Chitnis, T. & Khoury, S. J. Insights into the molecular pathogenesis of progression in multiple sclerosis. Potential implications for future therapies. Arch. Neurol. 63, 25–33 (2006).
Bar-Or, A. The immunology of multiple sclerosis. Semin. Neurol. 28, 29–45 (2008).
Rovaris, M. et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Ann. Neurol. 129, 2628–2634 (2006).
Calabrese, M. et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann. Neurol. 67, 376–383 (2010).
Acknowledgements
The authors are financially supported by research grants from the Immune Tolerance Network, the US Department of Defense, the National MS Society and the NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. A. Cohen has acted as a consultant for Eli Lilly, Genzyme, Novartis and Teva. He has also received research support from Biogen Idec, Genzyme, Novartis and Teva. D. S. Conway declares no competing interests.
Rights and permissions
About this article
Cite this article
Conway, D., Cohen, J. Mechanisms of disability accumulation in multiple sclerosis. Nat Rev Neurol 6, 654–655 (2010). https://doi.org/10.1038/nrneurol.2010.175
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.175
